Contact
searchSearch
HMP Global
Login

Schizophrenia Excellence Forum

Schizophrenia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Maria Mantas
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Shaping the Future of Schizophrenia Care With Muscarinic-Targeting Treatments
09/05/2025
Brooke Kempf, MSN, PMHNP-BC
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress...
09/05/2025
Psych Congress Network
Hara Oyedeji
Videos
Tackling Demographic Disparities in Schizophrenia Diagnosis
08/11/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP...
08/11/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Considerations for Incorporating Muscarinic Agonists Into Schizophrenia Treatment
08/05/2025
Craig Chepke, MD, DFAPA
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair...
08/05/2025
Psych Congress Network
Hara Oyedeji
Videos
Tips for Differentiating Schizophrenia From Underlying Mood Disorders
07/10/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
Filmed at the 2025 Psych Congress NP Institute in Orlando, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers practical tips for differentiating schizophrenia from underlying mood disorders, medication side effects, or other under-treated conditions.
Filmed at the 2025 Psych Congress NP Institute in Orlando, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers practical tips for differentiating schizophrenia from underlying mood disorders, medication side effects, or other under-treated conditions.
Filmed at the 2025 Psych...
07/10/2025
Psych Congress Network
Hara Oyedeji
Videos
Considering Oral Overlap Requirements When Initiating LAIs
06/12/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers guidance to clinicians navigating LAI initiation while considering oral overlap requirements.
In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers guidance to clinicians navigating LAI initiation while considering oral overlap requirements.
In this video, Hara Oyedeji,...
06/12/2025
Psych Congress Network
Hara Oyedeji
Videos
Expanding Your Schizophrenia Toolkit With Xanomeline-Trospium
06/03/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In part 2 of this series, Hara Oyedeji, APRN, PMHNP-BC, MSEd, unpacks the use and benefits of xanomeline-trospium as a treatment option for schizophrenia.
In part 2 of this series, Hara Oyedeji, APRN, PMHNP-BC, MSEd, unpacks the use and benefits of xanomeline-trospium as a treatment option for schizophrenia.
In part 2 of this series, Hara...
06/03/2025
Psych Congress Network
Philip Harvey, PhD
Q&As
Assessing EMA Outcomes in Xanomeline-Trospium Treatment for Schizophrenia
05/15/2025
In this expert Q&A, Philip D. Harvey, PhD, discusses the Ecological Momentary Assessment (EMA) sub studies that were completed as part of the EMERGENT-5 trial.
In this expert Q&A, Philip D. Harvey, PhD, discusses the Ecological Momentary Assessment (EMA) sub studies that were completed as part of the EMERGENT-5 trial.
In this expert Q&A, Philip D....
05/15/2025
Psych Congress Network
Hara Oyedeji
Videos
Effectively Managing Clozapine for Treatment-Resistant Schizophrenia
05/07/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, explores how APPs can most effectively prescribe and monitor patient progress on clozapine, the only FDA-approved treatment for treatment-resistant schizophrenia.
In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, explores how APPs can most effectively prescribe and monitor patient progress on clozapine, the only FDA-approved treatment for treatment-resistant schizophrenia.
In this video, Hara Oyedeji,...
05/07/2025
Psych Congress Network
Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
Brittany B. Albright, MD, MPH
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use